Clinical trials uncovering strategies in anticoagulation for sepsis, suggesting improved outcomes may arise from redefining outcome targets and treatment approaches.
Key Points
Recombinant activated protein C initially showed a survival benefit in severe sepsis but failed in later trials.
Studies on anticoagulant therapies in sepsis present mixed results, with some finding benefits and others showing limitations.
Key factors include treatment timing, dosage, and the appropriateness of 28-day mortality as an endpoint for sepsis trials.
Future clinical trials are focusing on coagulopathy in septic patients, adopting new endpoints to improve efficacy.